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High levels of serum vitamin B12 is principally due to vitamin supplementation
but it can be observed in several diseases such as solid neoplasms, hematological
malignancies and liver/kidney diseases. Vitamin B12 assay could be used as an
early diagnostic marker of these diseases. Some high results may, however, be
due to interference in the assay. Holotranscobalamin (HTC) is the active form of
cobalamin and represent ≈ 20% of the total Vitamin B12 concentration.
Material and Methods
In this study, we have selected 117 samples with Vitamin B12 value >1500 ng/L
on the Roche Cobas 6000 analyzer. Those samples were also analyzed for total
Vitamin B12 and HTC on the Abbott Architect i1000sr. We systematically treated
the samples with polyethyleneglycol (PEG 6000 40%) for 1h at 37°C and
reanalyzed them for the 3 previous tests.
Patients with serum total Vitamin B12 concentrations < 200 ng/L were classified
as deficient and borderline when total Vitamin B 12 concentration was between
200 and 300 ng/L. A cut-off of HTC concentration was set to discriminate
deficiency (< 35 pmol/L), sufficiency (35-128 pmol/L) and high (> 128 pmol/L).
Statistical analysis:
MedCalc software, version 12.7.7.0 (Oostende, Belgium) was used to perform
statistical analysis.
Conclusions
High prevalence of interference in patients with unexpected
high cobalamin level was found in this study. Some of them
were even deficient after PEG treatment. Precipitation with
PEG is an easy and costless way to decrease interference
of Vitamin B12 dosage and increase its reliability. HTC seems
to be differently impacted by the interferences since there
are deficient patients before PEG treatment with this assay.
HCT could be an alternative of systematic treatment of
unexpected high levels of Vitamin B12.
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Serum with cobalamin > 1500 ng/L represents 3,5% of the prescribed cobalamin
dosage. 
There is a drop in concentration after PEG treatment of 44 %, 41 % and 32 %
with Vitamin B12 Roche, Vitamin B12 Abbott and HTC respectively. A total of 35
patients (30 %) that presented serum total Vitamin B12 concentration > 1500
ng/L before PEG treatment were still showing results > 1500 ng/L after PEG
treatment on the Roche assay. Among the 117 patients, 4 (3,4 %) were HTC
deficient before any pretreatment. Conversely, 1,7 % of patients were deficient
for cobalamin after PEG treatment with Roche and 4,39 % with Abbott. 10.16 %
of the patients were borderline for cobalamin with Roche assay and 7,69 % of
them were with Abbott assay after PEG treatment. Also for HTC, there are 9,89




Figure 5 Distribution of Holotranscobalamin concentrations after PEG treatment
Figure 4 Distribution of cobalamin concentrations after PEG treatment
Figure 1
Architect B12 : Cobalamin values before 
treatment poorly correlates with
cobalamin values after PEG treatment.
y = 0,0283x + 949,58
R² = 0,0002
Figure 2
Roche B12 : Cobalamin values before 
treatment poorly correlates with
cobalamin values after PEG treatment.




Cobalamin values before treatment 
poorly correlates with
cobalamin values after PEG treatment.
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